Suchergebnisse - "Thuresson, Per-Olof"

PubPharm (14)

1

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma

enthalten in: Advances in therapy | 2020

von Thuresson, P. | Vander Velde, N. | Gupta, P. | +1

2

The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany

enthalten in: Journal of comparative effectiveness research | 2020

von Hofmann, S. | Himmler, S. | Ostwald, D. | +3

3

US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

enthalten in: Journal of comparative effectiveness research | 2020

von Betts, K. | Thuresson, P. | Felizzi, F. | +5

ErratumIn: J Comp Eff Res. 2021 Mar;10(4):337. - PMID 33416405

4

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma

enthalten in: Advances in therapy | 2020

von Thuresson, P. | Vander Velde, N. | Gupta, P. | +1

5

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma

enthalten in: Advances in therapy | 2020

von Thuresson, P. | Vander Velde, N. | Gupta, P. | +1

6

Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States

enthalten in: Leukemia & lymphoma | 2019

von Guzauskas, G. | Masaquel, A. | Thuresson, P. | +2

7

Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis

enthalten in: Journal of managed care & specialty pharmacy | 2017

von Fisher, M. | Nathan, S. | Hill, C. | +4

8

Health state utility values in locally advanced and metastatic breast cancer by treatment line : a systematic review

enthalten in: Expert review of pharmacoeconomics & outcomes research | 2016

von Paracha, N. | Thuresson, P. | Moreno, S. | +1

9

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies

enthalten in: ClinicoEconomics and outcomes research : CEOR | 2015

von McDonell, A. | Kiiskinen, U. | Zammit, D. | +7

10

Review of utility values for economic modeling in type 2 diabetes

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2014

von Beaudet, A. | Clegg, J. | Thuresson, P. | +2